Anticipated shortage
Aimovig 70 mg/mL injection
erenumab · 70 mg/mL injection
Aimovig
- Reported
- 12 March 2025
- Expected resolution
- 31 October 2025
- TGA reference
- TGA-MSI-2025-039
- Sponsor
- Novartis Pharmaceuticals Australia Pty Ltd
Reason for shortage
Novartis/Amgen global supply renegotiation impacting Australian market allocation for anti-CGRP migraine preventatives.
What to do
- 1.Ensure you have adequate stock — Collect your current prescription promptly to build a small buffer before the anticipated shortage begins.
- 2.Speak with your prescriber proactively — Discuss alternative options now, before the shortage occurs, so a plan is in place.
- 3.Monitor TGA updates — Anticipated shortages may be resolved before they become active. Check the TGA MSI database regularly.
Suggested alternatives
Same or related therapeutic class. Always discuss with your doctor or pharmacist before switching.
- Discuss alternative migraine prevention with neurologist
- Topiramate (Topamax) — oral migraine prevention option
Official resources
MedWatch is for informational purposes only and does not constitute medical advice. Never stop or change your medicines without consulting your doctor or pharmacist. In an emergency, call 000. Medication queries: National Medicines Line 1300 633 424.